CIPLA · Healthcare · Drug Manufacturers - Specialty & Generic
Composite scorecard: 54/100 — Quality 75 · Valuation 27 · Growth 69 · Momentum 29
| Share price | ₹1,441.60 |
| Market cap | ₹1.09 lakh Cr |
| P/E ratio | 24.0 |
| P/B ratio | 3.3 |
| ROE | 20.4% |
| ROCE | 21.5% |
| Dividend yield | 0.96% |
| Book value | ₹407.53 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹28,163 Cr | ₹3,862 Cr | 21.0% |
| 2025 | ₹27,548 Cr | ₹5,269 Cr | 26.0% |
| 2024 | ₹25,774 Cr | ₹4,154 Cr | 24.0% |
| 2023 | ₹22,753 Cr | ₹2,833 Cr | 22.0% |
| 2022 | ₹21,763 Cr | ₹2,547 Cr | 21.0% |
Cipla Limited, together with its subsidiaries, manufactures, develops, sells, and distributes pharmaceutical products in India, the United States, South Africa, and internationally. The company operates through Pharmaceuticals and New Ventures segments. It offers generic and branded generic medicines, vaccines, active pharmaceutical ingredients, and formulations for various therapeutic areas, such as MI, angina, heart disease, pulmonary disease, kidney failure, Alzheimer's disease, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, central nervous system, HIV/AIDS, respirator